Reduced moxifloxacin exposure in patients with tuberculosis and diabetes

被引：10

作者：

Dekkers, Bart G. J. ^{[1
]}

Bolhuis, Mathieu S. ^{[1
]}

ter Beek, Lies ^{[2
,3
,4
]}

de Lange, Wiel C. M. ^{[2
,3
]}

van der Werf, Tjip S. ^{[2
,5
]}

Alffenaar, Jan-Willem C. ^{[1
,6
]}

Akkerman, Onno W. ^{[2
,3
]}

机构：

[1] Univ Groningen, Univ Med Ctr Groningen, Dept Clin Pharm & Pharmacol, Hanzepl 1, NL-9713 GZ Groningen, Netherlands

[2] Univ Groningen, Univ Med Ctr Groningen, Dept Pulm Dis & TB, Groningen, Netherlands

[3] Univ Groningen, Univ Med Ctr Groningen, TB Ctr Beatrixoord, Haren, Netherlands

[4] Hanze Univ Appl Sci, Nutr & Dietet, Groningen, Netherlands

[5] Univ Groningen, Univ Med Ctr Groningen, Dept Internal Med, Groningen, Netherlands

[6] Univ Sydney, Sydney Sch Pharm, Fac Med & Hlth, Sydney, NSW, Australia

来源：

EUROPEAN RESPIRATORY JOURNAL | 2019年 / 54卷 / 03期

关键词：

PHARMACOKINETICS; RIFAMPIN; PLASMA;

D O I：

10.1183/13993003.00373-2019

中图分类号：

R56 [呼吸系及胸部疾病];

学科分类号：

摘要：

引用

页数：4

共 15 条

[1] Bilirubin as a Potential Causal Factor in Type 2 Diabetes Risk: A Mendelian Randomization Study [J].

Abbasi, Ali ;

Deetman, Petronella E. ;

Corpeleijn, Eva ;

Gansevoort, Ron T. ;

Gans, Rijk O. B. ;

Hillege, Hans L. ;

van der Harst, Pim ;

Stolk, Ronald P. ;

Navis, Gerjan ;

Alizadeh, Behrooz Z. ;

Bakker, Stephan J. L. .

DIABETES, 2015, 64 (04) :1459-1469

[2] Effect of Diabetes Mellitus on the Pharmacokinetics and Pharmacodynamics of Tuberculosis Treatment [J].

Alfarisi, Omamah ;

Mave, Vidya ;

Gaikwad, Sanjay ;

Sahasrabudhe, Tushar ;

Ramachandran, Geetha ;

Kumar, Hemanth ;

Gupte, Nikhil ;

Kulkarni, Vandana ;

Deshmukh, Sona ;

Atre, Sachin ;

Raskar, Swapnil ;

Lokhande, Rahul ;

Barthwal, Madhusudan ;

Kakrani, Arjun ;

Chon, Sandy ;

Gupta, Amita ;

Golub, Jonathan E. ;

Dooley, Kelly E. .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2018, 62 (11)

[3]

[Anonymous], 2018, Technical report on critical concentrations for drug susceptibility testing of medicines used in the treatment of drug-resistant tuberculosis

[4] Plasma Concentrations of Isoniazid and Rifampin Are Decreased in Adult Pulmonary Tuberculosis Patients with Diabetes Mellitus [J].

Babalik, Aylin ;

Ulus, Ismail Hakki ;

Bakirci, Nadi ;

Kuyucu, Tulin ;

Arpag, Huseyin ;

Dagyildizi, Lale ;

Capaner, Esen .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2013, 57 (11) :5740-5742

[5] Role of Therapeutic Drug Monitoring in Treatment Optimization in Tuberculosis and Diabetes Mellitus Comorbidity [J].

Dekkers, B. G. J. ;

Akkerman, O. W. ;

Alffenaar, J. W. C. .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2019, 63 (02)

[6]

Elsen SHJ, 2019, ANTIMICROB AGENTS CH, V63

[7] World Health Organization treatment guidelines for drug-resistant tuberculosis, 2016 update [J].

Falzon, Dennis ;

Schunemann, Holger J. ;

Harausz, Elizabeth ;

Gonzalez-Angulo, Lice ;

Lienhardt, Christian ;

Jaramillo, Ernesto ;

Weyer, Karin .

EUROPEAN RESPIRATORY JOURNAL, 2017, 49 (03)

[8] Can we predict tuberculosis cure? What tools are available? [J].

Goletti, Delia ;

Arlehamn, Cecilia S. Lindestam ;

Scriba, Thomas J. ;

Anthony, Richard ;

Cirillo, Daniela Maria ;

Alonzi, Tonino ;

Denkinger, Claudia M. ;

Cobelens, Frank .

EUROPEAN RESPIRATORY JOURNAL, 2018, 52 (05)

[9] Selection of a moxifloxacin dose that suppresses drug resistance in Mycobacterium tuberculosis, by use of an in vitro pharmacodynamic infection model and mathematical modeling [J].

Gumbo, T ;

Louie, A ;

Deziel, MR ;

Parsons, LM ;

Salfinger, M ;

Drusano, GL .

JOURNAL OF INFECTIOUS DISEASES, 2004, 190 (09) :1642-1651

[10] Exposure to rifampicin is strongly reduced in patients with tuberculosis and type 2 diabetes [J].

Nijland, Hanneke M. J. ;

Ruslami, Rovina ;

Stalenhoef, Janneke E. ;

Nelwan, Erni J. ;

Alisjahbana, Bachti ;

Nelwan, Ron H. H. ;

van der Ven, Andre J. A. M. ;

Danusantoso, Halim ;

Aarnoutse, Rob E. ;

van Crevel, Reinout .

CLINICAL INFECTIOUS DISEASES, 2006, 43 (07) :848-854

← 1 2 →